PAVmed Announces Firm Commitment Public Offering of Common Stock

PAVmed Inc. (Nasdaq: PAVM, PAVMW)) (“PAVmed”), a highly differentiated, multiproduct medical device company, today announced that it intends to offer shares of common stock in an underwritten public offering. PAVmed also expects to grant to the underwriters a 45-day option to purchase additional shares of common stock to cover overallotments, if any. PAVmed intends to use the net proceeds from this offering for working capital and other general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Dawson James Securities, Inc. is acting as the sole underwriter of the offering.

The offering is being made pursuant to a shelf registration statement (File No. 333-220549) declared effective by the Securities and Exchange Commission on October 6, 2017. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission. The securities may be offered only by means of a written prospectus forming a part of the effective registration statement. When available, copies of the prospectus supplement and accompanying base prospectus relating to the offering may be obtained from the Securities and Exchange Commission at http://www.sec.gov, or from Dawson James Securities, Inc., Attention: Prospectus Department, 1 North Federal Highway, 5th Floor, Boca Raton, FL 33432, [e-mail] or toll free at 866.928.0928.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, the shares of common stock. PAVmed will not, and has been advised by the underwriters that they and their affiliates will not, sell any of the shares of common stock in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About PAVmed

PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs, have attractive regulatory pathways and market opportunities and encompass a broad spectrum of clinical areas including carpal tunnel syndrome (CarpX™), interventional radiology (PortIO™ and NextCath™), pediatric ear infections (DisappEAR™) medical infusions (NextFlo™ and NextCath™), and tissue ablation and cardiovascular intervention (Caldus™). The Company intends to further expand its pipeline through engagements with clinician innovators and leading academic medical centers. For further information, please visit www.pavmed.com.